Parissa Farnia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8941044/publications.pdf

Version: 2024-02-01

		172207	182168
111	3,076	29	51
papers	citations	h-index	g-index
115	115	115	3760
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli. Chest, 2009, 136, 420-425.	0.4	524
2	Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nature Genetics, 2017, 49, 395-402.	9.4	258
3	Extensively Drugâ€Resistant Tuberculosis: 2 Years of Surveillance in Iran. Clinical Infectious Diseases, 2006, 43, 841-847.	2.9	134
4	Differences in Cell Wall Thickness between Resistant and Nonresistant Strains of <i>Mycobacterium tuberculosis</i> : Using Transmission Electron Microscopy. Chemotherapy, 2009, 55, 303-307.	0.8	115
5	Totally drug-resistant tuberculosis strains: evidence of adaptation at the cellular level. European Respiratory Journal, 2009, 34, 1202-1203.	3.1	78
6	First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iranâ€"eight years of surveillance. International Journal of Infectious Diseases, 2009, 13, e236-e240.	1.5	69
7	The NRAMPI, VDR and TNF- $\hat{l}\pm$ gene polymorphisms in Iranian tuberculosis patients: the study on host susceptibility. Brazilian Journal of Infectious Diseases, 2009, 13, 252-6.	0.3	69
8	Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients. Journal of Infection, 2006, 53, 331-336.	1.7	60
9	Anti-tuberculosis drug resistance and associated risk factors in a tertiary level TB center in Iran: a retrospective analysis. Journal of Infection in Developing Countries, 2011, 5, 511-519.	0.5	57
10	Adverse Effects of Multidrug-Resistant Tuberculosis Treatment With a Standardized Regimen: A Report From Iran. American Journal of Therapeutics, 2011, 18, e29-e34.	0.5	51
11	Bovis Bacillus Calmette–Guerin (BCG) infection induces exosomal miRNA release by human macrophages. Journal of Translational Medicine, 2017, 15, 105.	1.8	51
12	Lethal Tuberculosis in a Previously Healthy Adult with IL-12 Receptor Deficiency. Journal of Clinical Immunology, 2011, 31, 537-539.	2.0	49
13	Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran. International Journal of Infectious Diseases, 2005, 9, 317-322.	1.5	44
14	Improving Sensitivity of Direct Microscopy for Detection of Acid-Fast Bacilli in Sputum: Use of Chitin in Mucus Digestion. Journal of Clinical Microbiology, 2002, 40, 508-511.	1.8	43
15	The Recent-Transmission of Mycobacterium tuberculosis Strains among Iranian and Afghan Relapse Cases: a DNA-fingerprinting using RFLP and spoligotyping. BMC Infectious Diseases, 2008, 8, 109.	1.3	43
16	Incidence, Clinical and Epidemiological Risk Factors, and Outcome of Drug-Induced Hepatitis Due to Antituberculous Agents in New Tuberculosis Cases. American Journal of Therapeutics, 2010, 17, 17-22.	0.5	43
17	Nontuberculous mycobacteria in Middle East: Current situation and future challenges. International Journal of Mycobacteriology, 2015, 4, 7-17.	0.3	43
18	The NRAMP1, VDR, TNF-α, ICAM1, TLR2 and TLR4 gene polymorphisms in Iranian patients with pulmonary tuberculosis: A case–control study. Infection, Genetics and Evolution, 2016, 39, 92-98.	1.0	42

#	Article	IF	Citations
19	Proinflammatory cytokines can significantly induce human mononuclear phagocytes to produce nitric oxide by a cell maturation-dependent process. Immunology Letters, 1995, 48, 59-64.	1.1	39
20	Comparison between Molecular Epidemiology, Geographical Regions and Drug Resistance in <i>Mycobacterium tuberculosis</i> Strains Isolated from Iranian and Afghan Patients. Chemotherapy, 2006, 52, 316-320.	0.8	39
21	Pulmonary disease caused by Mycobacterium simiae in Iran's national referral center for tuberculosis. Journal of Infection in Developing Countries, 2012, 6, 23-28.	0.5	39
22	Molecular Epidemiology of Nontuberculous Mycobacteria Isolates from Clinical and Environmental Sources of a Metropolitan City. PLoS ONE, 2014, 9, e114428.	1.1	38
23	The most prevalent Mycobacterium tuberculosis superfamilies among Iranian and Afghan TB cases. Scandinavian Journal of Infectious Diseases, 2006, 38, 463-468.	1.5	36
24	Nontuberculous Mycobacteria Among Patients Who are Suspected for Multidrug-Resistant Tuberculosis—Need for Earlier Identification of Nontuberculosis Mycobacteria. American Journal of the Medical Sciences, 2009, 337, 182-184.	0.4	35
25	Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients. International Journal of STD and AIDS, 2012, 23, e1-e4.	0.5	35
26	<i>Mycobacterium tuberculosis</i> Genotypic Diversity in Pyrazinamide-Resistant Isolates of Iran. Microbial Drug Resistance, 2009, 15, 251-256.	0.9	34
27	Evaluation of tuberculosis transmission in Tehran: using RFLP and spoloigotyping methods. Journal of Infection, 2004, 49, 94-101.	1.7	33
28	High Prevelance of Rifampin-Monoresistant Tuberculosis: A Retrospective Analysis among Iranian Pulmonary Tuberculosis Patients. American Journal of Tropical Medicine and Hygiene, 2014, 90, 99-105.	0.6	33
29	Identification and Genotyping of Mycobacterium tuberculosis Isolated From Water and Soil Samples of a Metropolitan City. Chest, 2015, 147, 1094-1102.	0.4	33
30	Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy [Short communication]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 547-550.	0.6	30
31	The totally drug resistant tuberculosis (TDR-TB). International Journal of Clinical and Experimental Medicine, 2013, 6, 307-9.	1.3	30
32	The Most Predominant Spoligopatterns of <i>Mycobacterium tuberculosis</i> Isolates among Iranian, Afghan-Immigrant, Pakistani and Turkish Tuberculosis Patients: A Comparative Analysis. Chemotherapy, 2010, 56, 248-257.	0.8	26
33	Populations of latent Mycobacterium tuberculosis lack a cell wall: Isolation, visualization, and whole-genome characterization. International Journal of Mycobacteriology, 2016, 5, 66-73.	0.3	26
34	Colorimetric Detection of Multidrug-Resistant or Extensively Drug-Resistant Tuberculosis by Use of Malachite Green Indicator Dye. Journal of Clinical Microbiology, 2008, 46, 796-799.	1.8	25
35	Molecular Analysis of Isoniazid Resistance in Different Genotypes of <i>Mycobacterium tuberculosis</i> Isolates from Iran. Microbial Drug Resistance, 2008, 14, 273-279.	0.9	25
36	A Retrospective Analysis of Isoniazid-Monoresistant Tuberculosis: Among Iranian Pulmonary Tuberculosis Patients. Open Microbiology Journal, 2014, 8, 1-5.	0.2	25

#	Article	IF	CITATIONS
37	ASSOCIATION OF MYCOBACTERIUM TUBERCULOSIS LINEAGES WITH IFN-Γ AND TNF-ΠGENE POLYMORPHISMS AMONG PULMONARY TUBERCULOSIS PATIENT. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014015.	0.5	25
38	Trends of drug resistant Mycobacterium tuberculosis in a tertiary tuberculosis center in Iran. Journal of King Abdulaziz University, Islamic Economics, 2007, 28, 544-50.	0.5	25
39	BEIJING GENOTYPE AND OTHER PREDOMINANT MYCOBACTERIUM TUBERCULOSIS SPOLIGOTYPES OBSERVED IN MASHHAD CITY, IRAN. Indian Journal of Medical Microbiology, 2009, 27, 306-310.	0.3	24
40	Drug-resistant Mycobacterium tuberculosis: Epidemiology and role of morphological alterations. Journal of Global Antimicrobial Resistance, 2018, 12, 192-196.	0.9	24
41	Rapid and low-cost colorimetric method using 2,3,5-triphenyltetrazolium chloride for detection of multidrug-resistant Mycobacterium tuberculosis. Journal of Medical Microbiology, 2006, 55, 1657-1659.	0.7	23
42	New insight into extremely drug-resistant tuberculosis: using atomic force microscopy. European Respiratory Journal, 2010, 36, 1490-1493.	3.1	23
43	Application of Oxidation-Reduction Assay for Monitoring Treatment of Patients with Pulmonary Tuberculosis. Journal of Clinical Microbiology, 2004, 42, 3324-3325.	1.8	22
44	Impact of Extensively Drug-Resistant Tuberculosis on Treatment Outcome of Multidrug-Resistant Tuberculosis Patients with Standardized Regimen: Report from Iran. Microbial Drug Resistance, 2010, 16, 81-86.	0.9	22
45	Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. International Journal of Clinical and Experimental Medicine, 2010, 3, 308-14.	1.3	22
46	First insight into the drug resistance pattern of Mycobacterium tuberculosis in Dohuk, Iraq: Using spoligotyping and MIRU-VNTR to characterize multidrug resistant strains. Journal of Infection and Public Health, 2011, 4, 41-47.	1.9	20
47	Nontuberculous Mycobacteria Isolation from Clinical and Environmental Samples in Iran: Twenty Years of Surveillance. BioMed Research International, 2015, 2015, 1-10.	0.9	19
48	The role of interferon-gamma and interferon-gamma receptor in tuberculosis and nontuberculous mycobacterial infections. International Journal of Mycobacteriology, 2021, 10, 349.	0.3	19
49	Revised Category II Regimen as an Alternative Strategy for Retreatment of Category I Regimen Failure and Irregular Treatment Cases. American Journal of Therapeutics, 2011, 18, 343-349.	0.5	17
50	Estimation of Recent Transmission of Mycobacterium Tuberculosis Strains among Iranian and Afghan Immigrants: A Cluster-Based Study. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, DC05-8.	0.8	17
51	Overview of drug-resistant tuberculosis worldwide. International Journal of Mycobacteriology, 2016, 5, S161.	0.3	17
52	Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis. Journal of Global Antimicrobial Resistance, 2016, 4, 1-4.	0.9	17
53	Extensively drug-resistant tuberculosis treatment outcome in Iran: a case series of seven patients. International Journal of Infectious Diseases, 2010, 14, e399-e402.	1.5	16
54	Utility of gastric lavage for diagnosis of tuberculosis in patients who are unable to expectorate sputum. Journal of Global Infectious Diseases, 2011, 3, 339.	0.2	15

#	Article	IF	CITATIONS
55	Molecular diversity of Mycobacterium tuberculosis strains indifferent provinces of Iran. Iranian Journal of Microbiology, 2013, 5, 366-73.	0.8	15
56	Mycobacterium gastri causing disseminated infection in children of same family. Pediatric Pulmonology, 2005, 39, 284-287.	1.0	14
57	Synchronous Comparison of Mycobacterium tuberculosis Epidemiology Strains by "MIRU-VNTR" and "MIRU-VNTR" and Spoligotyping" Technique. Avicenna Journal of Medical Biotechnology, 2010, 2, 145-52.	0.2	14
58	Pili in totally drug resistant Mycobacterium Tuberculosis (TDR-TB). International Journal of Mycobacteriology, 2012, 1, 57-58.	0.3	13
59	Susceptibility to pulmonary tuberculosis in Iranian individuals is not affected by compound <i>KIR</i> / <i>HLA</i> genotype. Tissue Antigens, 2012, 79, 90-96.	1.0	13
60	Association of IFN- \hat{l}^3 and P2X7 Receptor Gene Polymorphisms in Susceptibility to Tuberculosis Among Iranian Patients. Acta Microbiologica Et Immunologica Hungarica, 2016, 63, 93-101.	0.4	13
61	Interferon-Gamma Receptor-1 Gene Promoter Polymorphisms and Susceptibility to Leprosy in Children of a Single Family. American Journal of Tropical Medicine and Hygiene, 2011, 84, 627-629.	0.6	12
62	Totally drug-resistant tuberculosis (TDR-TB): A debate on global health communities. International Journal of Mycobacteriology, 2013, 2, 71-72.	0.3	12
63	Rapid and Simultaneous Detection of Vitamin D Receptor Gene Polymorphisms by a Single ARMS-PCR Assay. Molecular Diagnosis and Therapy, 2014, 18, 97-103.	1.6	12
64	Human genetic background in susceptibility to tuberculosis. International Journal of Mycobacteriology, 2020, 9, 239.	0.3	12
65	Nontuberculous Mycobacteria: Epidemiologic, Mycobacteriologic, and Clinical Aspects. BioMed Research International, 2015, 2015, 1-2.	0.9	11
66	Sequential adaptation in latent tuberculosis bacilli: observation by atomic force microscopy (AFM). International Journal of Clinical and Experimental Medicine, 2011, 4, 193-9.	1.3	11
67	Bacteriological follow-up of pulmonary tuberculosis treatment: a study with a simple colorimetric assay. Microbes and Infection, 2004, 6, 972-976.	1.0	10
68	Instability of IS6110 patterns in multidrug-resistant strains of Mycobacterium tuberculosis. Epidemiology and Infection, 2007, 135, 346-352.	1.0	10
69	First-line antituberculosis drug resistance prevalence and its pattern among HIV-infected patients in the national referral tuberculosis centre, Iran. International Journal of STD and AIDS, 2009, 20, 566-570.	0.5	9
70	Synthesis and evaluation of in vitro anti-tuberculosis activity of N-substituted glycolamides. European Journal of Medicinal Chemistry, 2009, 44, 289-295.	2.6	9
71	Dihydropteroate synthase gene mutation rates in Pneumocystis jirovecii strains obtained from Iranian HIV-positive and non-HIV-positive patients. Medical Mycology, 2015, 53, 361-368.	0.3	9
72	Association of Interferon-Î ³ Receptor-1 Gene Polymorphism with Nontuberculous Mycobacterial Lung Infection among Iranian Patients with Pulmonary Disease. American Journal of Tropical Medicine and Hygiene, 2017, 97, 57-61.	0.6	9

#	Article	IF	Citations
73	Is standardized treatment appropriate for non-XDR multiple drug resistant tuberculosis cases? A clinical descriptive study. Scandinavian Journal of Infectious Diseases, 2009, 41, 10-13.	1.5	7
74	Typing ofPneumocystis jiroveciiisolates from Iranian immunosuppressed patients based on the Internal Transcribed Spacer (ITS) region of the rRNA gene. Medical Mycology, 2013, 51, 843-850.	0.3	7
75	Co-infection of Mycobacterium tuberculosis and Pneumocystis jirovecii in the Iranian Patients With Human Immunodeficiency Virus. Jundishapur Journal of Microbiology, 2015, 8, e17254.	0.2	7
76	Susceptibility to pulmonary tuberculosis: host genetic deficiency in tumor necrosis factor alpha (TNF-α) gene and tumor necrosis factor receptor 2 (TNFR2). International Journal of Mycobacteriology, 2016, 5, S136-S137.	0.3	7
77	An Overview of Genetic Information of Latent Mycobacterium tuberculosis. Tuberculosis and Respiratory Diseases, 2021, 84, 1-12.	0.7	7
78	Molecular detection of fluoroquinolone resistance-associated gyrA mutations in ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Iran and Belarus. International Journal of Mycobacteriology, 2016, 5, 299-305.	0.3	6
79	Morphological modification by tubercle bacilli: no time for denial. Journal of Infection in Developing Countries, 2012, 6, 97-99.	0.5	6
80	Colonization of Pneumocystis jirovecii in Chronic Obstructive Pulmonary Disease (COPD) patients and the rate of Pneumocystis pneumonia in Iranian non-HIV(+) immunocompromised patients. Iranian Journal of Microbiology, 2013, 5, 411-7.	0.8	6
81	Representative drug susceptibility patterns for guiding design of reâ€treatment regimens for multidrugâ€resistant tuberculosis in Iran. Respirology, 2008, 13, 108-111.	1.3	5
82	Isolation of Mycobacterium branderi, an unusual species from an acute myelogenous leukemia patient. Avicenna Journal of Medicine, 2014, 4, 17.	0.3	5
83	Association of Receptors, Purinergic P2X7 and Tumor Necrosis Factor-alpha Gene Polymorphisms in Susceptibility to Tuberculosis Among Iranian Patients. Archives of Clinical Infectious Diseases, 2013, 8,	0.1	5
84	Do mitochondrial DNA haplogroups play a role in susceptibility to tuberculosis?. Respirology, 2007, 12, 823-827.	1.3	4
85	Latent tuberculosis (TB) bacilli: Yes or no to preventive chemotherapy. International Journal of Mycobacteriology, 2012, 1, 1-2.	0.3	4
86	HIV and tuberculosis trends and survival of coinfection in a referral center in Tehran: A 12-year study. International Journal of Mycobacteriology, 2016, 5, S16-S17.	0.3	4
87	Rapid Detection of Isoniazid Resistance in Mycobacterium tuberculosis by a Single Multiplex Allele-specific Polymerase Chain Reaction Assay. Cell Journal, 2011, 13, 97-102.	0.2	4
88	Anti-tuberculosis drug resistance in Dohuk, Iraq. International Journal of Tuberculosis and Lung Disease, 2010, 14, 1213-4.	0.6	4
89	Modified Sleeve Anastomosis in Large Muscular Arteries of Sheep. European Journal of Vascular and Endovascular Surgery, 2005, 30, 381-385.	0.8	3
90	Differences in characteristics between Afghani and Iranian patients with pulmonary tuberculosis. International Journal of Infectious Diseases, 2007, 11, 180-182.	1.5	3

#	Article	IF	Citations
91	Investigation of urine lipoarabinomannan in human immunodeficiency virus patients with or without coinfection with Tuberculosis in Iran. International Journal of Mycobacteriology, 2016, 5, S186-S187.	0.3	3
92	Identification of different subtypes of rapid growing Atypical Mycobacterium from water and soil sources: Using PCR-RFLP using hsp65 and rRNA 16s–23s genes. International Journal of Mycobacteriology, 2016, 5, S212-S213.	0.3	3
93	Epidemiological Distribution of Nontuberculous Mycobacteria Using Geographical Information System., 2019, , 191-321.		3
94	Recurrence after treatment success in pulmonary multidrug-resistant tuberculosis: predication by continual PCR positivity. International Journal of Clinical and Experimental Medicine, 2012, 5, 271-2.	1.3	3
95	Comparison of single nucleotide polymorphisms [SNP] at TNF-α promoter region with TNF receptor 2 (TNFR2) in susceptibility to pulmonary tuberculosis; using PCR-RFLP technique. American Journal of Clinical and Experimental Immunology, 2016, 5, 55-61.	0.2	3
96	Division-cycle in Mycobacterium tuberculosis. International Journal of Mycobacteriology, 2012, 1, 111-117.	0.3	2
97	Rate of Pneumocystis pneumonia in Iranian HIV+ Patients with Pulmonary Infiltrates. Jundishapur Journal of Microbiology, 2013, , .	0.2	2
98	Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid? [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 849-850.	0.6	2
99	Deletion of region of difference 181 in Mycobacterium tuberculosis Beijing strains. International Journal of Mycobacteriology, 2016, 5, S238-S239.	0.3	2
100	Molecular drug susceptibility testing against the first-line (rifampin and isoniazid) and second-line (ciprofloxacin–amikacin and kanamycin) treatment in different subtypes of Mycobacterium simiae. International Journal of Mycobacteriology, 2016, 5, S215.	0.3	2
101	Characterization of Clinical Isolates of Mycobacterium simiae Using Drug Susceptibility Tests and Molecular Analyses. Current Microbiology, 2021, 78, 2324-2331.	1.0	2
102	Clinical and radiological deterioration due to Mycobacterium szulgai in an asthmatic patient. Journal of Infection in Developing Countries, 2012, 6, 89-91.	0.5	2
103	Susceptibility to tuberculosis among pulmonary tuberculosis patients: P2X7 and TNF-α gene polymorphisms. International Journal of Mycobacteriology, 2015, 4, 133.	0.3	1
104	Rapid identification of environmental NTM species using molecular genotyping. International Journal of Mycobacteriology, 2015, 4, 107.	0.3	1
105	Evaluation of p2x7 and IFN- \hat{l}^3 gene polymorphisms in patients with pulmonary tuberculosis using PCR-RFLP method. International Journal of Mycobacteriology, 2015, 4, 130.	0.3	1
106	Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide testing by MTBDRsl in Armenia. International Journal of Mycobacteriology, 2016, 5, S159-S160.	0.3	1
107	Distribution scheme of antituberculosis drug resistance among HIV patients in a referral centre over 10 years. Journal of Global Antimicrobial Resistance, 2017, 11, 116-119.	0.9	1
108	An 8-year study on the prevalence and drug resistance of mycobacteria in clinical specimens (2011–2018). Clinical Epidemiology and Global Health, 2020, 8, 557-561.	0.9	1

#	Article	IF	CITATIONS
109	Prevalence of Mycobacterium abscessus among the Patients with Nontuberculous Mycobacteria. Archives of Iranian Medicine, 2020, 23, 163-168.	0.2	1
110	Response. Chest, 2015, 147, e158-e159.	0.4	0
111	Default of treatment in patients with tuberculosis during 10years after standardized drug treatment. International Journal of Mycobacteriology, 2015, 4, 164.	0.3	0